Submitted by Anjali Fortna on Tue, 05/26/2015 - 2:46pm Please rate this CME activity. * Please use the scale: 1=Very poor, 2=Poor, 3=Neutral, 4=Good, 5=Excellent 12345 Overall evaluation Overall evaluation - 1 Overall evaluation - 2 Overall evaluation - 3 Overall evaluation - 4 Overall evaluation - 5 Content Content - 1 Content - 2 Content - 3 Content - 4 Content - 5 Usefulness Usefulness - 1 Usefulness - 2 Usefulness - 3 Usefulness - 4 Usefulness - 5 Quality Quality - 1 Quality - 2 Quality - 3 Quality - 4 Quality - 5 Please rate the extent to which each of the following learning objectives were met. * Please use the scale: 1=Strongly disagree, 2=Disagree, 3=Neutral, 4=Agree, 5=Strongly agree 12345 Review the recently released data for PD-1 therapies in the treatment of melanoma Review the recently released data for PD-1 therapies in the treatment of melanoma - 1 Review the recently released data for PD-1 therapies in the treatment of melanoma - 2 Review the recently released data for PD-1 therapies in the treatment of melanoma - 3 Review the recently released data for PD-1 therapies in the treatment of melanoma - 4 Review the recently released data for PD-1 therapies in the treatment of melanoma - 5 Analyze the strategies to apply novel PD-1 specific treatments to the care of patients with melanoma Analyze the strategies to apply novel PD-1 specific treatments to the care of patients with melanoma - 1 Analyze the strategies to apply novel PD-1 specific treatments to the care of patients with melanoma - 2 Analyze the strategies to apply novel PD-1 specific treatments to the care of patients with melanoma - 3 Analyze the strategies to apply novel PD-1 specific treatments to the care of patients with melanoma - 4 Analyze the strategies to apply novel PD-1 specific treatments to the care of patients with melanoma - 5 How many patients do you see with metastatic melanoma each month? * 0 1-10 11-20 21-30 31-40 41-50 51-60 >60 N/A: I don’t see any patients After participating in this activity, how confident are you in your ability to * Please use the scale: 1=NOT at all confident, 2=Not very confident, 3=Somewhat confident, 4=Confident, 5=Very confident 12345 Develop personalized treatment plans for patients with metastatic melanoma? Develop personalized treatment plans for patients with metastatic melanoma? - 1 Develop personalized treatment plans for patients with metastatic melanoma? - 2 Develop personalized treatment plans for patients with metastatic melanoma? - 3 Develop personalized treatment plans for patients with metastatic melanoma? - 4 Develop personalized treatment plans for patients with metastatic melanoma? - 5 Apply novel PD-1 specific therapeutics when treating your patients with metastatic melanoma? Apply novel PD-1 specific therapeutics when treating your patients with metastatic melanoma? - 1 Apply novel PD-1 specific therapeutics when treating your patients with metastatic melanoma? - 2 Apply novel PD-1 specific therapeutics when treating your patients with metastatic melanoma? - 3 Apply novel PD-1 specific therapeutics when treating your patients with metastatic melanoma? - 4 Apply novel PD-1 specific therapeutics when treating your patients with metastatic melanoma? - 5 As a result of participating in this activity, I will consider current clinical trial data on PD-1 therapies to improve outcomes of patients with metastatic melanoma. * Yes No Do you feel the activity was fair, balanced, and free of commercial bias? * Yes No Please explain: What topics would you like to see in future CME activities? Do you wish to be notified by email when new educational programs are offered by Elsevier? Yes No Please take a moment to reflect on your planned use of the practice strategies discussed in this activity. You will not be graded on your responses. Indicate how often you NOW PLAN to use these strategies based on your participation in this CME activity. * Please use the scale: 1=Never, 2=Not often, 3=Sometimes, 4=Often, 5=Always, N/A=Not applicable for me 12345N/A Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 1 Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 2 Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 3 Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 4 Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 5 Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - N/A Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 1 Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 2 Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 3 Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 4 Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 5 Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - N/A Leave this field blank
